Particle.news
Download on the App Store

HHS Bars Fetal Tissue From Elective Abortions in Federally Funded Research

The policy shifts federal research away from primary fetal tissue toward alternative models with exemptions for established cell lines.

Overview

  • HHS said the restriction is effective immediately across NIH grants, contracts, cooperative agreements, and intramural programs.
  • NIH Director Jay Bhattacharya framed the change as an investment in organoids, tissue chips, and computational biology to better model disease.
  • HHS press secretary Emily Hilliard clarified that “elective” refers to abortion on demand rather than medically necessary procedures.
  • NIH guidance says established human fetal cell lines, including HEK 293, remain eligible for use under agency funding.
  • The announcement coincided with the March for Life, where Vice President J.D. Vance endorsed the move, as the administration also initiated a fraud review of 38 Planned Parenthood affiliates’ PPP loans that the organization disputes.